Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Alzheimer's drug TB006 safety study halted early

NCT ID NCT05476783

First seen May 07, 2026 · Last updated May 21, 2026 · Updated 3 times

Summary

This study looked at the long-term safety of a drug called TB006 in people with Alzheimer's disease. It included people who had already been in a previous TB006 study and new participants. The study was stopped early, and it focused on tracking side effects and how the drug moved through the body, not on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinical Trial Site

    San Diego, California, 92103, United States

  • Clinical Trial Site

    Delray Beach, Florida, 33445, United States

  • Clinical Trial Site

    Lady Lake, Florida, 32159, United States

  • Clinical Trial Site

    Maitland, Florida, 32751, United States

  • Clinical Trial Site

    Miami, Florida, 33135, United States

  • Clinical Trial Site

    Miami, Florida, 33137, United States

  • Clinical Trial Site

    Miami, Florida, 33165, United States

  • Clinical Trial Site

    West Palm Beach, Florida, 33407, United States

  • Clinical Trial Site

    Winter Park, Florida, 32789, United States

  • Clinical Trial Site

    Winter Park, Florida, 32792, United States

  • Clinical Trial Site

    Decatur, Georgia, 30030, United States

  • Clinical Trial Site

    Matthews, North Carolina, 28105, United States

  • Clinical Trial Site

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.